GlassScriptPhysician profile
Hamzah Mansoura
NPI 1639668569
$558.14
in general payments reported to CMS, 2019-2025
12 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $40.22 · 2024: $111 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $175.33 | 2025 | 2nd Gen Centrimag Primary Console |
| Beyond Air, INC. | $102.36 | 2025 | Lungfit Ph |
| Merck Sharp & Dohme LLC | $59.70 | 2025 | Zerbaxa |
| Depuy Synthes Sales INC. | $45.53 | 2025 | Matrixmidface |
| Shionogi INC | $27.11 | 2024 | Fetroja |
| Kls-Martin L.P. | $26.09 | 2024 | |
| Haemonetics Corporation | $24.39 | 2025 | Teg6s Hemostasis System |
| Kci USA, INC. | $20.64 | 2023 | Prevena, V.A.C. Veraflo, Abthera Advance |
| Davol INC. | $19.91 | 2024 | |
| Csl Behring | $19.58 | 2023 | Kcentra |
| Smith+Nephew, INC. | $19.55 | 2024 | Versajet |
| Melinta Therapeutics, LLC | $17.95 | 2024 | Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamzah Mansoura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.